Do you know someone suffering from a mental health condition like depression, addiction, PTSD, or anxiety? Our guess is yes.
We all likely do, even if we don’t know it.
In North America alone, US$280B is spent annually on mental health treatment as we continue to claw through the global mental health crisis brought on by the pandemic.
While millions of our loved ones continue to struggle, exciting new developments in mental health treatment and drug development are emerging, showing promising results.
In the coming years, it’s possible these new treatments can help end our mental health crisis and drastically improve the lives of millions of people.
Enter the world of psychedelic drug treatments; one of the most important recent drug developments that even Hendrix would be psyched about.
Today, we are featuring a green energy company that’s delivering real innovation and leading the global clean energy revolution by leveraging green ammonia to decarbonize and disrupt traditional sectors.
Let’s dive into AmmPower 👇
Get Psyched About Psychedelics: A multi-trillion-dollar industry in the making
Yeah, We All Natural
Been There, Done That
The Bottom Line
By 2027, the psychedelics industry is set to total $10B, growing at a 16.3% CAGR between 2020 and 2027. Since first showing promise as a way to help treat difficult mental health issues, interest in the space has continued to grow rapidly.
As of 2021, $3B of venture money had been allocated globally to psychedelics and it’s only the beginning.
To date, most players in the psychedelics space have focused their efforts on the development of drugs and treatments around synthetically prepared compounds vs. the stuff you can get from nature like “magic mushrooms”.
You might say they are really trippin…
The research done related to synthetics has been amazing for the development of the psychedelic industry, but many are missing a potentially HUGE side of this exploding market. This opens opportunities for companies looking outside the road most traveled by current psychedelic drug developers.
The psychedelics industry is trading at current multi-year lows and has dropped 49% YTD, but increasing regulatory clarity and strengthening R&D are presenting interesting opportunities to take a 2nd look.
Enter Filament health, a different kind of psychedelic drug development company on a mission to solve the global mental health crisis by unlocking the healing power of natural psychedelics (mic drop).
Filament is focused on developing natural psychedelics given their broader consumer application potential, lower manufacturing cost, lower cost to administer, and opportunity for licensable IP creation.
Meanwhile, stuck on the notion that they are impossible to standardize (they’re not), that the FDA won’t approve (it has), and that IP protection is possible (wrong again), no other competitors are exploring natural compounds.
Filament, on the other, is living breathing proof that all three beliefs are incorrect – it has them all!
With the natural stuff, multiple compounds like active psychedelic ingredients can be extracted in patentable, concentrated, standardized, and consistent ways from things like plants and mushrooms.
While the consumer applications could get anyone psyched, the opportunities presented by the extraction process are nothing to balk at.
With the complex nature of the drug development process, it’s difficult for drugs to be genericized if the manufacturing technologies used to create them are patented.
Filament is way ahead and is generating revenue from its IP portfolio of nine confirmed patents with 33 on the way.
But that’s not how those focused on synthetics can play it.
Synthetics, are just a one-compound trick pony and tend to focus on pharmaceutical applications that are lengthy and expensive to complete.
By going down this route, a manufacturer ends up betting on the willingness of insurance companies to foot most of the end user’s bill for the drug to be used.
Who knows how much an insurance company or consumer would, or could pay for something like this if there was a better way?
Filament is taking a different approach and sees the vast opportunity for profitable, safe, standardized, and large-scale extraction of natural psychedelics, accessible for only a few dollars (not thousands).
Filament is the first to conduct an FDA-approved clinical trial of natural psychedelics but they’re not new to biomaterial extraction and commercialization.
This is an experienced team of scientists and entrepreneurs.
Before waging their war on mental health, the founders scaled their previous bio material extraction company Mazza Innovation to a $26M exit while the rest of the team collected decades of experience in medical sciences and IP development.
Despite the psychedelics industry’s recent challenges, the amount of investment going into this space continues to raise eyebrows.
Many people like to compare what’s happening with psychedelics to what happened with cannabis in its early days. As of November 3, 2022, the total market cap of cannabis stocks totaled ~USD $46.45B across 239 companies.
Sure, it took time to get there, but the fact that 264 million suffer from depression globally, 275 million suffer from anxiety globally and 21 million suffer from addiction globally should be enough to make you interested.
Near-term catalysts include potential FDA approval to treat trauma with certain types of psychedelics, patients in Canada already being treated with psychedelics for mental health disorders, and Alberta being the first Canadian province to regulate psychedelic drugs for therapeutic use.
With its focus on natural psychedelic compounds, differentiated IP, and excellent R&D and management teams, Filament Health represents a potential leader in a nascent space poised to transform an entire industry.
The information contained on this website has been prepared by the paid advertiser Filament Health. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser. Filament Health has paid $150,000 to have this content (in addition to other content on other social media sites) created and published. GetVersed is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.
The information contained on this website has been prepared by the paid advertiser. The publisher does not guarantee the accuracy or completeness of the information provided in this page. All statements and expressions herein are the sole opinion of the paid advertiser.
Grit Capital Corporation is a publisher of financial information, not an investment advisor. We do not provide personalized or individualized investment advice or information that is tailored to the needs of any particular recipient.
THE INFORMATION CONTAINED ON THIS WEBSITE IS NOT AND SHOULD NOT BE CONSTRUED AS INVESTMENT ADVICE, AND DOES NOT PURPORT TO BE AND DOES NOT EXPRESS ANY OPINION AS TO THE PRICE AT WHICH THE SECURITIES OF ANY COMPANY MAY TRADE AT ANY TIME. THE INFORMATION AND OPINIONS PROVIDED HEREIN SHOULD NOT BE TAKEN AS SPECIFIC ADVICE ON THE MERITS OF ANY INVESTMENT DECISION. INVESTORS SHOULD MAKE THEIR OWN INVESTIGATION AND DECISIONS REGARDING THE PROSPECTS OF ANY COMPANY DISCUSSED HEREIN BASED ON SUCH INVESTORS’ OWN REVIEW OF PUBLICLY AVAILABLE INFORMATION AND SHOULD NOT RELY ON THE INFORMATION CONTAINED HEREIN. INVESTORS SHOULD OBTAIN INDIVIDUAL FINANCIAL ADVICE BASED ON THEIR OWN CIRCUMSTANCES BEFORE MAKING AN INVESTMENT DECISION.
No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned.
Any projections, market outlooks or estimates herein are forward looking statements and are inherently unreliable. They are based upon certain assumptions and should not be construed to be indicative of the actual events that will occur. Other events that were not taken into account may occur and may significantly affect the returns or performance of the securities discussed herein. The information provided herein is based on matters as they exist as of the date of preparation and not as of any future date, and the publisher undertakes no obligation to correct, update or revise the information in this document or to otherwise provide any additional material.
The publisher, its affiliates, and clients of the publisher or its affiliates may currently have long or short positions in the securities of the companies mentioned herein, or may have such a position in the future (and therefore may profit from fluctuations in the trading price of the securities). To the extent such persons do have such positions, there is no guarantee that such persons will maintain such positions.
Neither the publisher nor any of its affiliates accepts any liability whatsoever for any direct or consequential loss howsoever arising, directly or indirectly, from any use of the information contained herein.